Marthe D'Ombrain

Super exciting to see our brain penetrant spleen tyrosine kinase inhibitor, QED-701, discovered by QEDDI (UniQuest), in the very capable hands of Molecule to Medicine in new company Lucia Bio: https://lnkd.in/e_NxEjMM Looking forward to seeing QED-701 benefit patients living with neurodegeneration.

115

12 Comments

📣 Weekly Highlights 📣 a.  Doma Biopharmaceutical (Suzhou) Co., Ltd has received FDA clearance of Investigational New Drug (IND) application for its first bispecific ADC DM001. On June 26, 2024, it also obtained Australia's CTN approval and is set to commence a Phase 1 clinical study. DM001 is a bispecific ADC designed to treat solid tumors by targeting both TROP2 and EGFR receptors. The bispecific antibody was assembled using common light chain antibodies produced by Renlite. Payload-linker of DM001 is named as BLD1102. b.  Huadong Medicine announced that the IND application for HDM2005 targeting the ROR1 receptor has received approval from the US FDA. This approval allows for Phase 1 clinical trials in the United States, with indications for advanced malignant tumor. Source: Doma & Huadong Medicine websites AsymBio is a leading CDMO with comprehensive solutions for Novel Drug Conjugates (NDCs). Contact us for more information: https://www.asymbio.com/ #ADC  #payload  #linker  #IND  #BLA  #FDA #NMPA  #bioconjugation  #innovation  #DS  #DP

10

Day 3 of #Bio2024 was focused on collaborations with Australia, and I was fortunate to be invited to the #Queensland Investment Roundtable at which a number of promising start-ups presented. The support from AusBiotech and MTPConnect, alongside the various state governments, working collaboratively for a unified Australian approach, is next level. From pitch training, funding support, and introductions, I sat back and watched a master class from various teams introducing founders to investors throughout the session. It is very clear that there is a very structured plan to drive better outcomes for #Australia through investment into #Biotech. The role of BIOTech New Zealand in mirroring this approach is essential; if we are to participate in the massive investment made in #Australia, and to play our part in creating better outcomes for humanity through applied biotechnological advances, we need to buy a seat at the table. We're doing our part from Bridgewest Ventures NZ and with the strategic investments into #Perth and #Adelaide with NovaCina, LumaCina - Bridgewest Perth Pharma, and BioCina by Bridgewest Group. Membership to an affiliated BioTech group and collaboration is key if we're to success from AsiaPac [blatant pitch to join BIOTech New Zealand]. #NewZealand #BioTech #Collaboration

54

2 Comments

📢 NEWS: Today AusBiotech and MTPConnect have released a discussion paper on critical life science growth issues ahead of our upcoming National Biotech and Medtech Development and Commercialisation Summit, on 19 November 2024 in Canberra.   Australia's life sciences sector is an essential part of Australia’s economy, supporting high-paying and skilled jobs, manufacturing exports, and underpinning the health and wellbeing of Australians. It is rightly recognised by the Australian Government as a critical sector that is essential for Australia’s future. Yet while we are in the top ten globally for research, we slip down to 30th for the translation and commercialisation of that research. The upcoming Summit will see AusBiotech and MTPConnect gather some of the country’s most senior leaders from a cross-section of the biotech and medtech sector to tackle these issues.    The joint discussion paper launched today unpacks Australian and global policy contexts, stubborn industry challenges, and barriers to achieving robust “Development and Commercialisation” outcomes. MTPConnect CEO Stuart Dignam said the discussion paper and 19 November Summit aim to harness industry insights and create a united voice to government ahead of the 2025 election. “Medical products are one of Australia’s most significant value-add exports, but gaps in biomedical and medical technology product development limit our ability to fully realise the commercial potential of our innovation prowess,” Mr Dignam said. Add your voice to the discussion The Summit is one part of the conversation, and your insights are crucial to ensuring the discussions and any outputs reflect the diverse perspectives of the industry. If you aren’t attending the Summit, we invite you to complete the survey to share your views. Check out the discussion paper and survey below: https://lnkd.in/gmAjHbFp Stuart Dignam, Hon. Jaala Pulford, Rebekah Cassidy, Erin McAllum, Duncan Macinnis, Lisa Dubé, Amelia Vom, Andrew Bowskill, Tracey Wilkinson, Dana Bell

49

Learn about the growth issues that lie ahead for the Aus biotech sector with this new discussion paper by AusBiotech and MTPConnect.

2

People Living with rare cancers in Australia still struggle to receive equity of access to genomic testing. This is critical as often treating these types of cancers requires a personalized approach where understanding the genomic profile of a particular cancer can make all the difference to survival. 🔬🧬   Early this year, a senate enquiry was held to examine this issue and a very high number of submissions highlighted the role genomics had to play.   📌The report has now been released and I’m pleased to see that there are many recommendations around genomics including:   #6 As a matter of priority, the Australian Government legislate a complete ban on genetic discrimination in life insurance. Jane Tiller (PhD) great to see this included. #7 The Australian Government investigate opportunities to increase equitable uptake and access to genomic screening and profiling for Australians. #8  The Australian Government closely monitor the outcomes of the DNA Screen study, and the implications of the study for the future development of population wide, preventive genomic screening programs. #9 The Australian Government, through the Medical Research Future Fund, extend funding for the ZERO Childhood Cancer Program beyond June 2025. Vanessa (Ness) Tyrrell #36 The Australian Government explore options to provide incentives to expand genomic research in Australia. https://lnkd.in/gF6f9PGu

55

1 Comment

The second participant in Cohort 2 underway this morning in the Phase 1b Clinical trial at CMAX Clinical Research in Adelaide. Primary objective to assess safety as well as collect data through a controlled, dose escalated clinical program with IV-infused psilocin (the active metabolite of psilocybin). Study participants undergo an initial infusion period over 20 minutes to reach a psychedelic state, followed by a 120 minute maintenance infusion period. The data generated from our oral psilocybin Phase 2a program (TRP-8802) in the United States and this world-first study of IV-infused psilocin (TRP-8803) in Australia, will enable Tryptamine Therapeutics [ASX:TYP] to rapidly move into our TRP-8803 Phase 2 clinical program, beginning with Binge Eating Disorder (BED). IV-infused psilocin has the potential to overcome many significant drawbacks of oral psilocybin including reducing the duration of psychedelic treatment to 1-2 hours (from 8-10 hours) and reducing the time required for a patient to reach a neuroplastic state to 20 minutes (from 2 hours). #Tryptherapeutics #psilocin #psilocybin #neuroplasticity #psychedelic #infusion #neuropsychiatry #cmax

150

4 Comments

A recent study in eJHaem led by Anoop Enjeti (MD, PhD) in collaboration with Otsuka and Prospection (Arif Alam, Vincent Caillet), highlights the importance of treatment adherence and the need for more treatment options for Myelodysplastic Syndromes (MDS). It also showcases the critical role patient-centric intelligence (#PCI) can play in deepening understanding of treatment performance and patient behaviors, on the path to improving patient outcomes. Title: “Real-world study of the use of azacitidine in myelodysplasia in Australia” 🟢 Read more on our blog 👉 https://lnkd.in/gxtGhMu9

20

IDT and Sanofi to manufacture mRNA vaccines under development Drug development company IDT Australia and pharmaceutical business Sanofi have signed an agreement for the good manufacturing practice (cGMP) manufacture of Sanofi’s mRNA vaccines now under development. The partners will collaborate to advance mRNA-based vaccine formulation, development and manufacture at IDT’s aseptic sterile injectables filling facilities in Melbourne (pictured) in volumes needed for clinical trials targeting a number of medical conditions. The facility is one of only a few such facilities in the Asia Pacific region. mRNA technology came to the fore during the Covid-19 pandemic with vaccines developed quickly using the new technology proving effective in protecting the public from disease. The value of initial services being provided by IDT is up to $3.5 million, with the agreement allowing for follow on work packages. #vaccines #pharmaceuticals #manufacturing #manufacturingnews #mRNA @sanofi @IDTAus Sanofi IDT Australia Limited Moderna https://lnkd.in/geiXiass

4

🚨 Presentation Alert: Overview of Proposed Changes to GMO Therapy Regulation in Australia 🚨 Australia's Gene Technology Act 2000 has been the cornerstone of GMO (Genetically Modified Organism) regulation for over two decades. However, with rapid advancements in genetic therapies, it’s time for an update. These proposed changes aim to modernize our approach to GMO regulation and align with international best practices while ensuring robust safety standards. BPR's latest presentation: "Overview of Proposed Changes to GMO Therapy Regulation in Australia", outlines the first significant revisions to the Act since its inception. The information presented focuses on the main changes to the gene technology scheme that affect regulation of GMO medicinal therapies and licence applications for these therapies.

1

📢 🆕 New insights from Australia from Omico’s Molecular Screening and Therapeutics (MoST) program! Our latest analysis highlights key findings in advanced thyroid cancer. The study shows that TP53 and PI-3 kinase/AKT pathway mutations are independent predictors of overall survival. These findings underscore the power of comprehensive genomic profiling to inform both prognosis and targeted therapy for patients battling with advanced thyroid cancer. These insights will help guide future treatment decisions and improve outcomes for patients with advanced thyroid cancer. 🙏Thank you to all contributors, especially the patients, involved with this project. https://lnkd.in/gm9m8dWM #PrecisionOncology #ThyroidCancer #ComprehensiveGenomicProfiling #CancerResearch #MoSTProgram #Omico #CancerMeetsItsMatch Elan Novis Anthony Glover #JohnGrady #AudreySilvestri Subotheni Thavaneswaran Frank Lin Mandy Ballinger David Thomas St Vincent's Private Hospital Sydney #StVincentsClinicalSchool, UNSW The Kinghorn Cancer Centre, Garvan Institute of Medical Research, NHMRC Clinical Trials Centre, University of Sydney #CentreforMolecularOncology

21

We are grateful to announce the successful first close of $20 million in Proto Axiom's Series B capital raise. This capital, entirely unallocated, is dedicated to fuelling new investments, with a clear mandate: to empower Australia’s leading scientists at the most critical stage—the very beginning. Australia has long been a global leader in research, yet our biotech sector has not lived up to its full potential. Government-subsidised programs have often crowded out private investment, while market power dynamics have led to rent-seeking behaviours. Moreover, exclusivity clauses often lack transparency, stifling innovation and delaying the path from discovery to patient care. As a result, ground-breaking ideas are not reaching the market, and our collective promise to advance public health remains unfulfilled. As such, our mission is to remove the barriers that politics often places in the path of scientific progress. Together, we're committed to transforming the future of Australian biotech, ensuring that the best ideas make it from the lab to the lives of those who need them most. https://lnkd.in/g5b3giSc -- Board: Gavin MacLaren, Kathy Connell, GAICD, Tom Harley, Nicholas von Guionneau, MD, Tristan Edwards Team: Lindsay Wu, Hugh Mc Gonagle, John Roach, Laura Wimberger, Marina Naidion, Nicholas Hunt (Endo) Strategic Advisors: Anand Gautam (Chair), The Hon Gabrielle Upton FAICD FRSN, Lawrence Gozlan, Michelle Burke, Simon Allen, Rob McInnes, Serge Scrofani Scientific Advisors: Brian Ledwith (Chair), Bart Kolodziejczyk OAM, Sara Althari, Swee Kheng Khor, William (Bill) Marshall, Michael Sierra, Russell Basser

328

43 Comments

The NCRIS Health Group warmly welcomes the release of Australia’s RNA Blueprint by the Australian Department of Industry, Science and Resources. The NCRIS Health Group includes Bioplatforms Australia, EMBL Australia, National Imaging Facility, Phenomics Australia, Population Health Research Network and Therapeutic Innovation Australia. We are delighted that our advanced translational research infrastructure has been recognised in the RNA Blueprint. Supported by the Australian Department of Education’s National Collaborative Research Infrastructure Strategy (NCRIS), the NCRIS Health Group facilitates cross-disciplinary health and medical research, providing Australian researchers with access to world-class infrastructure that enhance outcomes across the entire translation cycle for various therapeutic products, including RNA-based therapies. The blueprint acknowledges that over $160M has been collectively invested by NCRIS Health Group members to establish an RNA Products Capability, enhance and expand synthetic biology capability and provide models for disease studies. We are committed to leveraging our research infrastructure capabilities to contribute to the blueprint’s identified goals to drive the growth of Australia’s RNA sector, particularly the connection and promotion of the national RNA ecosystem and increasing access to cutting edge national research infrastructure. We look forward to collaborating with the Department of Industry, Science and Resources to implement the actions outlined in the blueprint. Read the RNA Blueprint here - https://lnkd.in/g-xQxC2r

8

💡 Publication spotlight! In this study, published by our customer Monash University in Nature Portfolio, read about the 𝗵𝘂𝗺𝗮𝗻 𝗽𝗮𝗻𝗰𝗿𝗲𝗮𝘁𝗶𝗰 𝗱𝘂𝗰𝘁𝗮𝗹 𝗽𝗿𝗼𝗴𝗲𝗻𝗶𝘁𝗼𝗿 𝗰𝗲𝗹𝗹𝘀 𝗮𝘀 𝗮 𝗽𝗿𝗼𝗺𝗶𝘀𝗶𝗻𝗴 𝘀𝗼𝘂𝗿𝗰𝗲 𝗳𝗼𝗿 𝗿𝗲𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗻𝗴 β-𝗰𝗲𝗹𝗹𝘀 𝗳𝗼𝗿 𝗧𝟭𝗗. Utilizing 𝗘𝗻𝗱𝗼𝗖-β𝗛𝟱® 𝗰𝗲𝗹𝗹𝘀, which express a transcriptomic profile similar to that of mature, healthy human pancreatic beta cells, this research exposes an epigenetic mediated strategy to 𝗿𝗲𝗽𝗿𝗼𝗴𝗿𝗮𝗺 𝘁𝗲𝗿𝗺𝗶𝗻𝗮𝗹𝗹𝘆 𝗱𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝘁𝗶𝗮𝘁𝗲𝗱 𝗮𝗱𝘂𝗹𝘁 𝗵𝘂𝗺𝗮𝗻 𝗽𝗮𝗻𝗰𝗿𝗲𝗮𝘁𝗶𝗰 𝗱𝘂𝗰𝘁𝗮𝗹 𝗰𝗲𝗹𝗹𝘀 𝗶𝗻𝘁𝗼 𝗶𝗻𝘀𝘂𝗹𝗶𝗻-𝗽𝗿𝗼𝗱𝘂𝗰𝗶𝗻𝗴 β-𝗹𝗶𝗸𝗲 𝗰𝗲𝗹𝗹𝘀 by specifically addressing default suppression mediated by the EZH2 methyltransferase. Discover how this study highlights the potential of EZH2 inhibitors as a 𝗽𝗿𝗼𝗺𝗶𝘀𝗶𝗻𝗴 𝗻𝗲𝘄 𝘁𝗼𝗼𝗹 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗿𝗲𝘀𝘁𝗼𝗿𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 β-𝗹𝗶𝗸𝗲 𝗰𝗲𝗹𝗹 𝗳𝘂𝗻𝗰𝘁𝗶𝗼𝗻! 🔗 Read the full publication here: https://lnkd.in/ewPd78aK Learn more about EndoC-βH5® capabilities and how they can help your 𝗿𝗲𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝘃𝗲-𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗲𝗻𝗱𝗲𝗮𝘃𝗼𝗿𝘀: https://lnkd.in/ee2Gi7_m #Research #Type1Diabetes #DiabetesResearch #Pancreas #RegenerativeMedicine #HumanCellDesign #EndocBH5 #BiomedicalResearch

21

1 Comment

I'm excited to share that Ketim Therapeutics has been successful in the Industry Growth Program from the Department of Industry, Science and Resources for startups undertaking innovative commercialisation and/or growth projects that are within the priority areas of the Australian Government’s National Reconstruction Fund (NRF) and help build Australia’s manufacturing capability for the future. This is the first step to get through, being accepted for the #advisory program allows me to work with my advisor to develop recommendations and a plan for #commercialisation and/or growth including advice tailored to #Ketim, growth #strategies, business model #validation, #funding, #capital raising, IP, market testing and more 😍 This will help me be eligible to apply for the IGP's grants of $50,000 to $250,000 to support early-stage commercialisation projects and grants of $100,000 to $5 million for commercialisation and growth projects after completion of my advisory stage. I can't wait to start working with my allocated Industry Growth Program Advisor, Tony Aitchison and his amazing credentials :) Excited for what’s next!💼🚀 #IndustryGrowth #Innovation #BusinessGrowth #Commercialisation #Biotech #MedTech #Pharma #Startup

33

1 Comment

I greatly enjoyed the #AusBiotech2024 panel on “The lack of female leadership in Australian biotech”. Chaired by Michelle Burke, the panelists Rebecca McQualter, Dr Anna Lavelle AM FTSE GAICD , Bronwyn Le Grice and Gavin Fox-Smith discussed how we can change the tide. There was some good news: 27% of CEOs of private biotech companies in Australia are female. Much more than I thought it would be so that was great to hear. There are still big issues: Public companies with female leadership are rare. If boards have female Directors the setup is rarely 50/50. Women in leadership are still asked ridiculous questions like “aren’t you too young to be in this role” and “but who looks after your kids”. So what can we do?! ➡️ Women, let’s stop apologising for our success, frankness and for taking up space. ➡️ Counter silly questions with silly answers (“Why are you asking? Who’s looking after your kids?!”) ➡️ Let’s take issues seriously and let’s not pretend all works has been done. ➡️ realise the old excuse of “there just aren’t enough qualified women around to fill these roles” is complete BS. There are scores of highly qualified women there. And if you can’t think of anyone off the top of your head then do the work. Ask someone (preferably a woman) to refer suitable candidates. Do some research. So let’s try and get to a world in which gender balanced boards and management teams are the norm! #genderequity #womeninbiotech #AusBio2024

44

3 Comments

Genetic testing services in Australia are increasing in number over time, with diagnostic rates and utilization increasing as we move from panel to WES/WGS. However, the number of reanalyses is not increasing, despite the rapid addition of new disease variants and improved analysis methods, and the need to regularly reanalyze data. This is because, according to the survey results, “while genetic testing is reimbursed, reanalysis is not, leaving laboratories and clinical laboratories to cover the cost of scarce staffing at their own expense.” 3billion is your ally in solving these problems for healthcare providers. It updates new information every night and continuously reanalyzes undiagnosed patient data so you can focus on patient care. #WES_WGS #Reanalysis #3billion #raredisease https://lnkd.in/gkg9C4-A

14

Professors Deborah Schofield and Rupendra Shrestha of Macquarie University (Sydney, Australia), pioneers in the application of microsimulation modelling to genomics and precision medicine, recently sat down with us to discuss latest developments and their recent research. With the increasing availability of high quality genomic data, it’s an exciting time to be in the field, as microsimulation, with its ability to simulate individual behaviours and interactions, is ideally suited for handling heterogeneity in genetic differences, and can play a pivotal role in the evolving landscape of genomics and precision medicine. Read the highlights of the conversation here>> https://lnkd.in/eD7y6-Dj #microsimulation #precisionmedicine #genomics #pharmacogenomics #genomicmodelling

11